| Excerpt | Reference |
|---|
| "During treatment of active pulmonary tuberculosis with isoniazid, rifampicin and ethambutol in 15 patients transaminase activity increased in seven to levels of 60-340 U/l (group I)." | ( Austerhoff, A; Kindler, U; Knop, P, 1977) |
| "Patients in whom pulmonary tuberculosis had been newly diagnosed and confirmed bacteriologically were given standard triple chemotherapy with streptomycin, PAS and isoniazid for 6 weeks or 3 months." | ( , 1976) |
| "Initial chemotherapy of active pulmonary tuberculosis in contacts of known drug-resistant patients should be based on drug susceptibility studies in the index case." | ( Fairshter, RD; Garlin, J; Randazzo, GP; Wilson, AF, 1975) |
| "In this study, pulmonary tuberculosis was treated on an ambulatory basis, with the patients engaging in their usual activities and with a shortened period of chemotherapy." | ( Pilheu, JA, 1977) |
| "A 45-year-old man treated for pulmonary tuberculosis with daily drug therapy, including rifampin, developed acute renal failure manifested by ebinophilia, skin rash, and increased serum blood urea nitrogen and creatinine." | ( Bansal, VK; Bennett, D; Molnar, Z, 1977) |
| "In patients with chronic pulmonary tuberculosis the results of chemotherapy between drug regimens containing ethambutol or rifampicin were compared." | ( Cesarz-Fronczyk, M; Pregowski, W; Stanczuk, A; Znaniecka, H, 1976) |
| "59 patients with far advanced chronic pulmonary tuberculosis were treated, after a three months daily period of RMP/EMB and a third drug, with RMP 1." | ( Frenzel, I; Neumeyer, D, 1976) |
| "Twenty-nine patients with extensive pulmonary tuberculosis and drug-induced hepatitis were treated with ofloxacin along with other relatively non-hepatotoxic drugs, either during the interim phase to await recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others." | ( Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1992) |
| "Patients with direct smear positive pulmonary tuberculosis were admitted to hospital during the initial phase of treatment for two months." | ( Abdi, A; Lema, E; Roscigno, G; Wolde, K, 1992) |
| "A 33-year-old man with AIDS and pleuro-pulmonary tuberculosis was treated with a combination of antituberculous medications for 12 months and with continuation of isoniazid." | ( Jones, WD; Shafer, RW, 1991) |
| "For a study of fatality in pulmonary tuberculosis in England and Wales, a sample (n = 1222) of patients notified in 1983 as having tuberculosis confined to the lungs was selected and their mortality up to the time of finishing chemotherapy calculated." | ( Cullinan, P; Meredith, SK, 1991) |
| "The treatment of 77 pulmonary tuberculosis patients with zixoryn in the course of chemotherapy resulted in a lower incidence of toxic and allergic reactions and acute hepatitis, and a faster normalization of altered biochemical indices as compared to controls." | ( Mezhebovskiĭ, VR, 1990) |
| "250 patients suffering from pulmonary tuberculosis who were smear positive received a chemotherapy regime for 6 months combining Rifampicin and Isoniazid every day with a daily supplement of Pyrazinamide for the first 8 weeks." | ( Agounitestane, D; Ait Khaled, N; Boulahbal, F; Chaulet, P; Chiheb, M; Khaled, S, 1990) |
| "In 80 patients with pulmonary tuberculosis aggravated by stage I-IIB cardiopulmonary insufficiency, the multimodality therapy included vektarion improving the ventilation/perfusion correlations (29 patients) and the combination of metabolic correctors (glutamevit and riboxin) (51 patients)." | ( Balta, NG; Kaminskaia, GO; Khomenko, AG; Kryzhanovskiĭ, DG; Serebrianaia, BA, 1990) |
| "In Zimbabwe patients with pulmonary tuberculosis who are acid-fast bacilli (AFB) negative in the sputum are treated in the two month intensive phase with isoniazid, thiacetazone pyrazinamide and streptomycin (regimen A)." | ( Kusema, T; Mhonda, M; Neill, P; Nhachi, CF; Pringle, D, 1990) |
| "One hundred and seventeen children with pulmonary tuberculosis underwent treatment with a 6-month daily regimen of rifampin (15 mg/kg/day) and isoniazid (10 mg/kg/day)." | ( Assis, I; Bedran, MB; Moura, JA; Reis, FJ; Rodrigues, ME, 1990) |
| "Five patients with pulmonary tuberculosis suffered a relapse after treatment." | ( Morland, L, 1990) |
| "Two patients with pulmonary tuberculosis developed cutaneous vasculitis after antituberculosis treatment and a patient with tuberculous lymphadenitis developed vasculitis at presentation before drug therapy." | ( Chan, CH; Chong, YW; Hoheisel, GB; Sun, AJ, 1990) |
| "667 patients with newly diagnosed pulmonary tuberculosis were randomly allocated to continue daily treatment with isoniazid (400 mg) and rifampicin (600 mg) or to twice-weekly treatment with isoniazid (900 mg) and rifampicin (600 mg)." | ( Castelo, A; da Silva, EA; Dalboni, MA; Goihman, S; Haynes, RB; Jardim, JR; Kalckman, AS, 1989) |
| "Treatment of pulmonary tuberculosis was realized with rifadin, isoniazid and streptomycin." | ( Akhtyrskiĭ, AI; German, AK; Shevchenko, RN; Smirnova, VV, 1989) |
| "Patients with pulmonary tuberculosis who were failures of primary chemotherapy with strains resistant to isoniazid or to isoniazid and streptomycin were allocated at random to receive a regimen of rifampicin and ethambutol for 6 (4RE) or 9 months (7RE), supplemented in both treatment series by streptomycin plus pyrazinamide for the first 2 months." | ( Aluoch, JA; Babu Swai, O; Darbyshire, JH; Edwards, EA; Githui, WA; Nunn, AJ; Thiong'o, R, 1988) |
| "The outcome of treatment for pulmonary tuberculosis using isoniazid and rifampin for 9 months supplemented by ethambutol for the initial 2 months was evaluated in a cohort of 233 patients." | ( Hopewell, PC; Schecter, GF; Slutkin, G, 1988) |
| "The results indicate that pulmonary tuberculosis is associated with a high degree of undernutrition, but this improves with effective chemotherapy." | ( Harries, AD; Nkhoma, WA; Nyangulu, DS; Thompson, PJ; Wirima, JJ, 1988) |
| "Two patients with non-miliary pulmonary tuberculosis developed a syndrome resembling adult respiratory distress following initiation of drug treatment." | ( Onwubalili, JK; Scott, GM; Smith, H, 1986) |
| "Twenty patients with chronic pulmonary tuberculosis completed eight months of rifampin-ethambutol treatment." | ( Eidus, L; Jeanes, CW; Jessamine, AG, 1972) |
| "Chemotherapy of pulmonary tuberculosis was effective for existing disease in all ages and prevented dissemination." | ( Hsu, KH, 1984) |
| "In 1979 two patients with cavitary pulmonary tuberculosis were treated by a combination of three tuberculostatic drugs." | ( Schulthess, HK; Zollikofer, H, 1981) |
| "Patients with culture-positive pulmonary tuberculosis were allocated at random into two groups for a three-phase regimen in original course chemotherapy." | ( Favez, G; Leuenberger, P, 1982) |
| "Patients aged over 50 with pulmonary tuberculosis were treated with streptomycin and isoniazid administered by the routine routes and in the form of ultrasound aerosols." | ( Korablev, VN, 1982) |
| "Twenty-five patients who had extensive pulmonary tuberculosis and hepatitis induced by antituberculosis drugs were treated with ciprofloxacin together with other relatively non-hepatotoxic drugs, either during the interim phase awaiting recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others." | ( Chan, CY; Chau, CH; Cheng, AF; Cheung, SW; Lee, J; Wong, CF; Wong, PC; Yew, WW, 1995) |
| "After the pulmonary tuberculosis was improved by chemotherapy that included RFP, administration of Isoniazid and RFP was continued." | ( Ger, YC; Kawamura, S; Nagai, Y; Ohara, A; Otani, M; Tada, T, 1995) |
| "He had been treated for pulmonary tuberculosis since October 1988." | ( Abe, Y; Miyazawa, H; Sasaki, Y; Sugimoto, N; Suzuki, K; Yamagishi, F, 1995) |
| "120 patients with chronic destructive pulmonary tuberculosis received etiotropic therapy." | ( Archakova, LI; Ivanova, LA; Pavlova, MV, 1994) |
| "The patient with active pulmonary tuberculosis was successfully treated with a modified antituberculous drug regimen while taking standard doses of immunosuppressive drugs after transplantation." | ( Esquivel, CO; Farrell, FJ; Imperial, JC; Keeffe, EB; Man, KM, 1994) |
| "Of 5,100 patients with pulmonary tuberculosis who were admitted to our hospital during 12 years since January 1970 through 1981, 1,344 patients had no previous antituberculous drug therapy." | ( Baba, H, 1994) |
| "A patient with a history of pulmonary tuberculosis was treated in 1949 with Lucite sphere plombage thoracoplasty." | ( Harland, RW; Rosenzweig, DY; Sharma, M, 1993) |
| "One hundred fifty nine retreatment pulmonary tuberculosis cases admitted to Fukujuji Hospital were retrospectively analyzed." | ( Mori, T; Ogata, H; Seita, A; Sugie, T; Sugita, H; Wada, M, 1993) |
| "For patients with pulmonary tuberculosis that is resistant to rifampin and isoniazid, even the best available treatment is often unsuccessful." | ( Ackerson, L; Goble, M; Horsburgh, CR; Iseman, MD; Madsen, LA; Waite, D, 1993) |
| "Patients with cavitating pulmonary tuberculosis continue to excrete viable tubercle bacilli for approximately 6 weeks despite supervised treatment." | ( Morris, CD, 1996) |
| "The re-treatment pulmonary tuberculosis with positive spits represent 13." | ( Kayantao, D; Keïta, B; Sangaré, S, 1997) |
| "We report a technique for treatment of pulmonary tuberculosis that has become resistant to traditional antibiotics." | ( Bhagwanani, NS; Bhatia, GC; Sharma, N, 1996) |
| "A prospective study of 235 consecutive pulmonary tuberculosis (TB) patients admitted to Hospital Jamot in Yaounde, Cameroon, in a 6-month period in 1994 investigated the HIV seroprevalence in these patients and compared the incidence of adverse skin reactions in HIV-positive and HIV-negative patients receiving thiacetazone-free anti-TB treatment." | ( Bercion, R; Koulla-Shiro, S; Kuaban, C, 1997) |
| "Two patients with multidrug-resistant pulmonary tuberculosis were surgically treated after 3 and 7 years of unsuccessful chemotherapy." | ( Kuś, J; Michałowska-Mitczuk, D, 1997) |
| "A total of 41 patients with active pulmonary tuberculosis were studied at the outset and after 6 months of antimicrobial chemotherapy." | ( Anderson, R; Fickl, H; Pendel, S; Plit, ML; Theron, AJ; van Rensburg, CE, 1998) |
| "Overall, the effects of pulmonary tuberculosis and of its therapy on the thyroid function parameters examined, in otherwise healthy individuals, appear to be minimal." | ( Boufas, A; Christakopoulou, J; Filippou, N; Ilias, I; Panoutsopoulos, G; Tselebis, A, 1998) |
| "Current therapy for pulmonary tuberculosis involves 6 months of treatment with isoniazid, pyrazinamide, rifampin, and ethambutol or streptomycin for reliable treatment efficacy." | ( Alder, JD; Chu, D; Ewing, P; Jarvis, K; Meulbroek, J; Mitten, M; Nukkula, M; Oleksijew, A; Paige, L; Tovcimak, A, 1998) |
| "He was diagnosed with pulmonary tuberculosis with pericardial involvement and treated accordingly." | ( Cartier, P; Dumesnil, JG; Gobeil, F, 1998) |
| "The management of pulmonary tuberculosis (TB) in Scotland in 1993 was studied by asking the physicians responsible for all 321 adult cases of the disease notified that year to complete a standardized questionnaire relating to drug treatment and bacteriology." | ( Heald, SH; Leitch, AG; Simpson, AJ; Sudlow, MF; Watt, B, 1998) |
| "We studied 51 pulmonary tuberculosis patients who were initially treated with pyrazinamide (PZA) at our hospital between April 1996 and December 1997." | ( Ikeda, N; Ikeda, T; Inoue, T; Kurasawa, T; Nakatani, K; Sato, A; Yoshimatsu, H, 1999) |
| "Out of 1128 new pulmonary tuberculosis patients, six-hundred twenty started treatment with six-month (2HRZS or E/4HRE) in Fukujuji Hospital, JATA, in Tokyo from January 1991 to December 1996." | ( Ito, K; Mizutani, S; Ogata, H; Sugita, H; Wada, M; Yoshiyama, T, 1999) |
| "To study the characteristics of pulmonary tuberculosis complicated with legionnaires disease (LD) to avoid misdiagnosis and incorrect treatment." | ( Gao, W; Huang, X; Kong, Z, 1997) |
| "Untreated HIV positive patients with pulmonary tuberculosis did not have increased levels of urinary NO2-/NO3- (1101+/-614 microM, n = 6)." | ( Aderaye, G; Britton, S; Gebre, N; Schön, T; Sundqvist, T, 1999) |
| "We report a case of pulmonary tuberculosis with acute renal failure caused by readministration of Rifampicin (RFP)." | ( Kuroda, F; Mizutani, F; Sasaki, Y; Wada, A; Yagi, T; Yamagishi, F, 1999) |
| "He was diagnosed as pulmonary tuberculosis complicated with subcutaneous phaeohyphomycosis caused by Exophiala jeanselmei and was successfully treated with anti-tuberculosis drugs and anti-fungal agent, 5-fluorocytosine." | ( Dobashi, K; Mita, Y; Mori, M; Nakazawa, T, 2000) |
| "Japanese in-patients with pulmonary tuberculosis and normal liver function receiving treatment with isoniazid and rifampicin (INH + RMP)." | ( Azuma, J; Fukuda, T; Igarashi, T; Ito, M; Komuta, K; Maeda, K; Maekura, R; Ogura, T; Ohno, M; Yamaguchi, I; Yamamoto, I; Yamamoto, Y; Yokota, S, 2000) |
| "Treatment of DT is same as that for pulmonary tuberculosis." | ( Vijayan, VK, 2000) |
| "tuberculosis infection, mice with pulmonary tuberculosis induced by intranasal administration of virulent M." | ( Florquin, S; Juffermans, NP; Leemans, JC; van der Poll, T; van Deventer, SJ; van Rooijen, N; Verbon, A; Vervoordeldonk, MJ, 2001) |
| "Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation." | ( Ma, W; Yan, B; Zhu, L, 1998) |
| "An HIV-positive patient presented with pulmonary tuberculosis as her AIDS-defining diagnosis in 1993 and was effectively treated with 12 months of standard antituberculosis medications (isoniazide, rifampin, and pyrazinamide for 2 months)." | ( Jevtovic, D; Metlas, R; Stringer, WW; Veljkovic, V, 2001) |
| "115 cases of the senile pulmonary tuberculosis with bacteriological positive were divided into therapy group(group A) and control group(group B1 and B2) randomly." | ( Hu, X; Wang, J; Yu, D, 2001) |
| "A 36-month-old girl was treated for pulmonary tuberculosis (Mycobacterium tuberculosis) with isoniazid, rifampin and pyrazinamide." | ( Bettendorf, M; Meyburg, J; Nützenadel, W; Schmidt, KG, 2002) |
| "A total of 1472 pulmonary tuberculosis patients who had taken anti-tuberculosis treatment were evaluated retrospectively with respect to their drug resistance pattern by sputum culture for acid-fast bacilli (AFB) and sensitivity testing with isoniazid, rifampicin, streptomycin and ethambutol (E)." | ( Agarwal, SK; Shah, AR; Shah, KV, 2002) |
| "Fifty patients with drug-resistant pulmonary tuberculosis were managed by withdrawing all anti-tuberculosis drugs until the results of a drug sensitivity test were obtained (approximately 3 months), and then a 12-month self-administered regimen with four to six anti-tuberculosis drugs at full daily doses was initiated, based primarily on the sensitivity test and secondarily on the history of previous treatment." | ( Martínez-Rossier, LA; Pérez-Guzmán, C; Torres-Cruz, A; Vargas, MH; Villarreal-Velarde, H, 2002) |
| "Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months." | ( Badaró, R; Bandeira, AC; Barberin, MG; Brites, C; Guerra, C; Netto, EM; Pedral-Sampaio, DB, 2003) |
| "Treatment of pulmonary tuberculosis with these compounds was popularized, particularly by Danish physicians, in the mid-1920s, despite consistently negative experimental results, based on Paul Ehrlich's theories of antimicrobial drug effects." | ( Benedek, TG, 2004) |
| "A hundred new cases of active pulmonary tuberculosis whose age was 60 to 87 years were treated by the intensive chemotherapy regimen recommended by the WHO." | ( Karachunskiĭ, MA; Uvarova, TE, 2004) |
| "To estimate serum vitamin A in pulmonary tuberculosis (PTB) patients at the start and end of anti-tuberculosis treatment." | ( Baskaran, D; Fathima, R; Garg, R; Iliayas, SA; Narayanan, PR; Ramachandran, G; Santha, T; Venkatesan, P, 2004) |
| "This is the first case of pulmonary tuberculosis in a patient treated with infliximab in Japan." | ( Katoh, K; Kawai, T; Kudo, M; Okouchi, A; Taniguchi, H, 2004) |
| "The year long chemotherapy in pulmonary tuberculosis results in dose related side effects and may not reach atelectatic areas." | ( Banerjee, R; Chimote, G, 2005) |
| "It is unclear whether or not pulmonary tuberculosis may be induced by imatinib mesylate treatment, but caution is warranted in immunocompromised GIST patients." | ( Goto, T; Igaki, N; Kanda, S; Matsuda, T; Ohyama, M; Takashima, M; Tamada, F, 2005) |
| "Out of 222 adolescents with pulmonary tuberculosis, 115 received a short-term intensive DOTS chemotherapy and 107 had a conventional triple antibacterial treatment (TAT) regimen." | ( Balashova, NA; Guseĭnov, GK; Pakhieva, KhIu, 2006) |
| "Adults with smear-positive pulmonary tuberculosis were randomized in a factorial design to receive moxifloxacin (400 mg) versus ethambutol given 5 d/wk versus 3 d/wk (after 2 wk of daily therapy)." | ( Burman, WJ; Chaisson, RE; Choudhri, S; Daley, CL; Engle, M; Goldberg, S; Johnson, JL; Mosher, AW; Munsiff, SS; Muzanye, G; Vernon, A; Zhao, Z, 2006) |
| "A 38-year-old man with pulmonary tuberculosis developed purpura over both lower extremities and renal disturbance after starting antituberculosis treatment." | ( Fukunaga, M; Ito, Y; Kitamura, H; Shimizu, K; Tai, H; Takeda, H, 2007) |
| "He was diagnosed as pulmonary tuberculosis, and started treatment with INH, RFP, EB, and PZA." | ( Izumi, S; Taniguchi, H, 2007) |
| "Twenty-nine patients with pulmonary tuberculosis received glutoxim therapy (a study group)." | ( Bogadel'nikova, IV; Sinitsyn, MV, 2007) |
| "New smear-positive pulmonary tuberculosis (PTB) patients in the Revised National Tuberculosis Control Programme (RNTCP) are treated with a 6-month short-course chemotherapy (SCC) regimen irrespective of co-morbid conditions." | ( Adhilakshmi, AR; Balasubramanian, R; Banu Rekha, VV; Iliayas, S; Narayanan, PR; Rahman, F; Ramachandran, R; Selvakumar, N; Sundaram, V; Swaminathan, S; Thyagarajan, K, 2007) |
| "Incidence and prevalence of pulmonary tuberculosis in the present study was assessed in a blind manner by an active field survey and also retrospectively by history of anti tuberculosis treatment received by the patient in the intervening period (since vaccination), which was also corroborated by scrutinizing the medical records." | ( Adhikari, T; Benara, SK; Chauhan, DS; Katoch, K; Katoch, VM; Lavania, M; Sachan, AS; Sharma, VD; Singh, HB; Singh, P, 2008) |
| "The patients with drug susceptible pulmonary tuberculosis treated with 2HRZE/4H2R2 under the supervision by the pharmacists or the patients treated with 2HRZE/4HR by self-administration were followed-up for two years after completion of chemotherapy." | ( Hoshino, H; Mitarai, S; Ogata, H; Ohmori, M; Okumura, M; Uchimura, K; Wada, M; Yoshiyama, T, 2008) |
| "A total number of 135 pulmonary tuberculosis patients were treated with 2HRZE/4H2R2, 3 of 135 discontinued this intermittent treatment, and 11 of 135 completed chemotherapy was excluded from the relapse analysis, 105 out of the remaining 121 were followed-up for more than 6 months." | ( Hoshino, H; Mitarai, S; Ogata, H; Ohmori, M; Okumura, M; Uchimura, K; Wada, M; Yoshiyama, T, 2008) |
| "He had been treated for pulmonary tuberculosis for 6 months." | ( Ito, A; Kiyokawa, H; Nakashima, R; Suzuki, Y; Takafuji, S, 2008) |
| "Patients with cavitary pulmonary tuberculosis (TB) on baseline chest radiograph (CXR) who remain culture-positive after 8 weeks of treatment are at high risk of relapse." | ( Goodman, PC; Hamilton, CD; Johnson, JL; Khan, A; Menzies, R; Mosher, A; Schluger, NW; Stout, JE; Vernon, AN, 2008) |
| "In drug-responsive and drug-resistant pulmonary tuberculosis, unidirectional pretreatment changes were generally recorded in the activity of apoptosis and the spectrum of chemical elements of peripheral blood lymphocytes, which were most pronounced after completion of a phase of intensive antituberculosis chemotherapy." | ( Baranova, OV; Filiniuk, OV; Ivanova, EV; Novitskiĭ, VV; Shil'ko, TA; Strelis, AK; Tkachenko, SB; Urazova, OI; Voronkova, OV, 2008) |
| "Twenty-eight patients with pulmonary tuberculosis were evaluated at three time points: pretreatment (T0), treatment month 3 (T3) and treatment month 6 (T6)." | ( Calvi, SA; Marcondes-Machado, J; Peresi, E; Silva, SM, 2008) |
| "Coexistence of pulmonary tuberculosis (TB) and lung cancer in clinic poses significant challenges for the diagnostic and treatment of both diseases." | ( Bronson, RT; Kramnik, I; Nalbandian, A; Pichugin, A; Yan, BS, 2009) |
| "rifampicin (RMP) for the treatment of pulmonary tuberculosis (PTB)." | ( Gao, XF; Li, J; Li, YP; Yang, ZW, 2009) |
| "Treatment for hepatitis C and pulmonary tuberculosis were completed after 6 months." | ( Hung, CH; Lin, MC; Tsai, MC, 2009) |
| "We report the case of a patient with pulmonary tuberculosis and severe ARDS (PaO2/FiO2<100 mmHg) who was initially managed with advanced up-to-date treatments (protective ventilation and extracorporeal membrane oxygenation, ECMO) but failed to improve." | ( Bellani, G; Bombino, M; Confalonieri, A; Foti, G; Mauri, T; Patroniti, N; Pesenti, A; Zanella, A, 2012) |
| "An 86-year-old male with pulmonary tuberculosis developed fever, rash, and interstitial pneumonia 3 weeks after the beginning of treatment with isoniazid (INH), rifampicin (RFP), and ethambutol (EB)." | ( Kurasawa, T; Nishio, C; Sato, A; Sumi, K; Tsuboi, T, 2011) |
| "The study group consisted of 50 pulmonary tuberculosis patients before treatment and after 6 months of anti-tubercular therapy." | ( Fatemi, N; Javadian, S; Kordi, T; Mirkhani, F; Pourfallah, F; Sadeghi, S; Saghiri, R; Zamani, Z; Zarea, B, 2011) |
| "The number of pulmonary tuberculosis (PTB) patients reported with resistance to first-line anti-tuberculosis drugs after a standardized retreatment regimen in Cameroon is increasing." | ( Abena Foe, JL; Fon, E; Noeske, J; Voelz, N, 2012) |
| "Treatment for a 51-year-old man with pulmonary tuberculosis was initiated with isoniazid, rifampicin, ethambutol, and pyrazinamide, and discontinued after 3 weeks because of skin rash and itchiness." | ( Cho, YJ; Hwang, YS; Jeong, YY; Kim, HC; Kim, YE; Lee, EJ; Lee, JD; Lee, SH; Lee, SJ, 2012) |
| "Ex vivo blood samples from 27 pulmonary tuberculosis patients were assayed at diagnosis and during treatment." | ( Cho, JE; Clark, TG; Cliff, JM; Constantinou, N; Dockrell, HM; Duncan, K; King, EC; Lee, JS; Lukey, PT; Ronacher, K; Van Helden, PD; Walzl, G, 2013) |
| "She had pulmonary tuberculosis and developed a fever, systemic exudative erythema, exanthema, and epidermolysis covering 30% of her body surface area while being treated with four agents, including isoniazid (INH) and rifampicin (RFP)." | ( Mimori, A; Takahashi, Y; Ueda, Y; Yamashita, H, 2012) |
| "Sputum smear positive pulmonary tuberculosis patients expel infectious viable bacilli for a period following commencement of treatment." | ( Kanade, S; Khatri, V; Mehta, P; Nataraj, G; Parikh, R, 2012) |
| "We report the case of a patient with pulmonary tuberculosis, whose diagnosis was delayed because of prior treatment with fluoroquinolone and metronidazole." | ( Ema, R; Morioka, S; Nakamura, H; Sakurai, A; Tomita, K, 2013) |
| "Newly diagnosed pulmonary tuberculosis (PTB) patients starting treatment under the Revised National Tuberculosis Control Programme (RNTCP) in a North Indian city." | ( Aggarwal, AN; Gupta, D; Janmeja, AK; Jindal, SK, 2013) |
| "Therefore, pulmonary tuberculosis, including reactivation, should be considered in the differential diagnosis when treating a patient with sorafenib." | ( Cho, T; Emura, M; Igarashi, S; Kobayashi, Y; Nakamura, T; Nomizo, T; Nomura, N; Seto, R, 2013) |
| "The risk of pulmonary tuberculosis (PTB) may increase with increased use of anti-tumour necrosis factor (TNF) treatment in inflammatory arthritis." | ( Chang, SC; Huang, LK; Wu, MH, 2014) |
| "The patient was a 27-year-old man with pulmonary tuberculosis, who was initially treated with isoniazid, rifampicin, ethambutol, and pyrazinamide." | ( Anzai, M; Ikeda, N; Katsube, O; Kikkawa, Y; Nomura, Y; Numao, T; Takizawa, H, 2014) |
| "The strains were isolated from a pulmonary tuberculosis patient before and after drug treatment." | ( Dobos, KM; Mehaffy, C; Nieto R, LM, 2016) |
| "One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| "Since the patient was suspected to have pulmonary tuberculosis based on the clinical and radiological findings, empirical antituberculosis therapy was started." | ( Acar, M; Ağaçfidan, A; Aktürk, H; Beka, H; Hançerli Törün, S; Karagöz, N; Salman, N; Somer, A; Sütçü, M; Yekeler, E, 2016) |
| "Ninety patients with new-onset pulmonary tuberculosis were examined prior to therapy The patients were randomized into 2 groups: 1) 20 patients receiving the standard antibiotic therapy regimen; 2) 70 patients taking the standard antibiotic therapy and the polyenzyme drug Wobenzym." | ( Ievlev-Duntau, AP; Lipsky, KA; Shkurupiy, VA; Trunov, AN; Yakimova, AV, 2010) |
| "The patient was diagnosed with pulmonary tuberculosis (TB) and received anti-TB treatment with isoniazid, RFP, ethambutol, and pyrazinamide (PZA) at her local hospital." | ( He, JQ; Ji, G; Sandford, AJ; Zeng, X, 2016) |
| "HIV complicates every aspect of pulmonary tuberculosis from diagnosis to treatment, demanding a different approach to effectively tackle both the diseases." | ( Chandrasekaran, P; Gopalan, N; Swaminathan, S; Tripathy, S, 2016) |
| "33 patients with pulmonary tuberculosis were treated with one Risorine kit, daily consisting of one capsule of Risorine, one tablet of ethambutol (800 mg) and two tablets of Pyrazinamide 750 mg each, for first two months of therapy." | ( Patel, K; Patel, S; Vora, A, 2016) |
| "One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of therapy, and PK parameters determined using nonlinear mixed-effects models." | ( Denti, P; Gumbo, T; Lesosky, M; McIlleron, H; Meintjes, G; Pasipanodya, JG; Rockwood, N; Sirgel, F; Wilkinson, RJ, 2017) |
| "Upon diagnosis, Pulmonary Tuberculosis patients are treated for TB for a period of 6-9 months." | ( Indumati, V; Krishnaswamy, D; Rajeshwari, V; Ramesh, A; Shantala, D; Shilpa, A; Vijay, V, 2017) |
| "She had been previously diagnosed with pulmonary tuberculosis elsewhere and prescribed antitubercular therapy; however, there was little improvement in her symptoms." | ( Goyal, A; Joshi, D; Khurana, A; Khurana, U; Malik, R; Sharma, J, 2018) |
| "Forty patients with pulmonary tuberculosis and pneumonia were divided into 2 groups: observation group (n = 20), patients treated with linezolid; control group (n = 20), patients treated with moxifloxacin." | ( Ding, RD; Zhang, HJ, 2018) |
| "Patients with pulmonary tuberculosis who were administered intravenous drugs were elderly and in poor general health." | ( Akagawa, S; Ishida, M; Kawashima, M; Matsui, H; Nagai, H; Ota, K; Shimada, M; Suzuki, J; Tamura, A; Yamane, A, 2016) |
| "We present a case of pulmonary tuberculosis treated with a rifampicin (RMP) containing regimen, which led to marked haemolysis and acute kidney injury." | ( Kennedy, N; McGoldrick, C; Raafat, A; Shepherd, J; Sykes, CA, 2019) |
| "Presumptive pulmonary tuberculosis (PTB) patients whose sputum are detected to be smear negative for acid fast bacilli (AFB) present a significant challenge for a treating physician." | ( Bansal, M; Chopra, S; Chopra, V; Chungath, J; Singh Virk, B, 2020) |
| "The interaction of vitamin A and D on pulmonary tuberculosis treatment has not been studied." | ( Liu, Y; Ma, A; Wang, J; Wang, Q; Xiong, K; Zhao, S, 2020) |
| "The incidence of pulmonary tuberculosis (PTB) can be reduced by preventing transmission with rapid and precise case detection and early treatment." | ( Emran, NA; Hossain, ABMT; Kabir, S; Parash, MTH; Shimmi, SC, 2021) |
| "Diagnosis of extrapulmonary tuberculosis may be more challenging than pulmonary tuberculosis, which may lead to delay in starting treatment." | ( Can Sarınoğlu, R; Duman, N; Karahasan Yağcı, A; Küçüksu, U; Ünlü, N, 2021) |
| "In participants with pulmonary tuberculosis who were subsequently cured, the location of cavitary and non-cavitary lesions at baseline and new lesions at week 4 of treatment suggest a cavitary origin of disease and bronchial spread through the lungs." | ( Arora, K; Barry, CE; Cai, Y; Chen, RY; Dawson, R; Diacon, AH; Gao, J; Goldfeder, LC; Jin, X; Liu, X; Malherbe, ST; Pan, S; Qu, Y; Smith, B; Tameris, M; Thienemann, F; Vincent, J; Walzl, G; Wang, J; Wilkinson, RJ; Yu, X; Zhang, R; Zhu, H, 2021) |
| "In patients with rifampin-resistant pulmonary tuberculosis, a 24-week, all-oral regimen was noninferior to the accepted standard-care treatment, and it had a better safety profile." | ( Berry, C; Dodd, M; du Cros, P; Fielding, K; Kazounis, E; Liverko, I; McHugh, TD; Moodliar, R; Moore, DAJ; Motta, I; Ngubane, N; Nyang'wa, BT; Parpieva, N; Rassool, M; Ritmeijer, K; Solodovnikova, V; Spigelman, M; Tigay, Z, 2022) |
| "Patients with pulmonary tuberculosis may present with deterioration of pleural effusion during anti-tuberculosis therapy, referred to as a paradoxical response (PR), with some patients requiring additional intervention." | ( Kodama, T; Morimoto, K; Ohta, K; Okumura, M; Shimoda, M; Tanaka, Y; Yoshimori, K; Yoshiyama, T, 2023) |